aztreonam

Summary

Summary: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.

Top Publications

  1. LaPlante K, Sakoulas G. Evaluating aztreonam and ceftazidime pharmacodynamics with Escherichia coli in combination with daptomycin, linezolid, or vancomycin in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2009;53:4549-55 pubmed publisher
    In an in vitro pharmacodynamic model, linezolid attenuated the activity of aztreonam and ceftazidime against Escherichia coli...
  2. Pendland S, Messick C, Jung R. In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2002;42:75-8 pubmed
    The synergistic potential of levofloxacin, ofloxacin and ciprofloxacin combined with aztreonam, ceftazidime, or piperacillin was compared using 24 strains of Pseudomonas aeruginosa with varying susceptibility profiles...
  3. Jeong S, Kim W, Chang C, Kim J, Lee K, Chong Y, et al. Neonatal intensive care unit outbreak caused by a strain of Klebsiella oxytoca resistant to aztreonam due to overproduction of chromosomal beta-lactamase. J Hosp Infect. 2001;48:281-8 pubmed
    Klebsiella oxytoca strains resistant to both aztreonam and ceftriaxone were isolated from six neonates in a neonatal intensive care unit and water reservoirs of two humidifiers attached to the neonatal incubators...
  4. McCoy K, Quittner A, Oermann C, Gibson R, Retsch Bogart G, Montgomery A. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:921-8 pubmed publisher
    The effectiveness and safety of aztreonam lysine for inhalation (AZLI) in patients with cystic fibrosis (CF) on maintenance treatment for Pseudomonas aeruginosa (PA) airway infection was evaluated in this randomized, double-blind, ..
  5. Adinolfi L, Utili R, Dilillo M, Tripodi M, Attanasio V, Ruggiero G. Intracellular activity of cefamandole and aztreonam against phagocytosed Escherichia coli and Staphylococcus aureus. J Antimicrob Chemother. 1989;24:927-35 pubmed
    The intracellular activity of cefamandole and aztreonam against phagocytosed Escherichia coli and cefamandole against phagocytosed Staphylococcus aureus was studied using a sensitive and standardized method of murine peritoneal ..
  6. Crandon J, Nicolau D. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-?-lactamase producers. Antimicrob Agents Chemother. 2013;57:3299-306 pubmed publisher
    Secondary to the stability of aztreonam against metallo-?-lactamases, coupled with avibatam's neutralizing activity against often coproduced extended-spectrum ?-lactamases (ESBLs) or AmpC enzymes, the combination of aztreonam and ..
  7. Hutchinson D, Barclay M, Prescott W, Brown J. Inhaled aztreonam lysine: an evidence-based review. Expert Opin Pharmacother. 2013;14:2115-24 pubmed publisher
    ..describes the pharmacology, pharmacodynamics/pharmacokinetics, clinical efficacy, microbiology and safety of aztreonam lysine (AZLI, Cayston), an inhaled antibiotic indicated for use in CF patients with PA...
  8. Dudley M, Ambrose P, Bhavnani S, Craig W, Ferraro M, Jones R. Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam. Clin Infect Dis. 2013;56:1301-9 pubmed publisher
    ..This paper summarizes the background and supportive rationale for new interpretative criteria for cephalosporins and aztreonam for testing Enterobacteriaceae.
  9. Wong S, Sorgel F, Kinzig M, Goldberg M, Kitt M, Barriere S. Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants. J Clin Pharmacol. 2009;49:816-23 pubmed publisher
    This randomized crossover study in healthy participants assessed pharmacokinetic interactions between telavancin, aztreonam, and piperacillin/tazobactam...

More Information

Publications62

  1. Corey G, Wilcox M, Talbot G, Friedland H, Baculik T, Witherell G, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51:641-50 pubmed publisher
    ..the clinical cure rate achieved with ceftaroline monotherapy, compared with that achieved with vancomycin plus aztreonam combination therapy, in the clinically evaluable (CE) and modified intent-to-treat (MITT) patient populations...
  2. Sacchidanand S, Penn R, Embil J, Campos M, Curcio D, Ellis Grosse E, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Int J Infect Dis. 2005;9:251-61 pubmed
    ..monotherapy, a first-in-class, expanded broad spectrum glycylcycline, with the combination of vancomycin and aztreonam (V + A) in the treatment of complicated skin and skin structure infections (cSSSI)...
  3. Sakurai Y, Yoshida Y, Saitoh K, Nemoto M, Yamaguchi A, Sawai T. Characteristics of aztreonam as a substrate, inhibitor and inducer for beta-lactamases. J Antibiot (Tokyo). 1990;43:403-10 pubmed
    b>Aztreonam was investigated as to its characteristics as a substrate, inhibitor and inducer for the well-defined beta-lactamases of Gram-negative bacteria, and its antibacterial efficacy as to bacterial cells producing eight types of beta-..
  4. Araoka H, Baba M, Tateda K, Ishii Y, Oguri T, Okuzumi K, et al. In vitro combination effects of aztreonam and aminoglycoside against multidrug-resistant Pseudomonas aeruginosa in Japan. Jpn J Infect Dis. 2012;65:84-7 pubmed
    The aim of this study was to evaluate the in vitro combination effects of aztreonam (AZT) and aminoglycosides against multidrug-resistant (MDR) Pseudomonas aeruginosa strains in Japan. We investigated 47 MDR P...
  5. Wertheim H, Verbrugh H, van Pelt C, de Man P, van Belkum A, Vos M. Improved detection of methicillin-resistant Staphylococcus aureus using phenyl mannitol broth containing aztreonam and ceftizoxime. J Clin Microbiol. 2001;39:2660-2 pubmed
    We tested a phenyl mannitol broth containing ceftizoxime and aztreonam (PHMB(+)) for detection of methicillin-resistant Staphylococcus aureus (MRSA) with reference MRSA strains and, subsequently, with clinical samples (n = 1,098)...
  6. Muratani T, Akasaka S, Kobayashi T, Yamada Y, Inatomi H, Takahashi K, et al. Outbreak of cefozopran (penicillin, oral cephems, and aztreonam)-resistant Neisseria gonorrhoeae in Japan. Antimicrob Agents Chemother. 2001;45:3603-6 pubmed
    ..reported that the Neisseria gonorrhoeae isolates from clinical failure cases treated with cefdinir and aztreonam, beta-lactams exhibited high MICs...
  7. Akasaka S, Muratani T, Yamada Y, Inatomi H, Takahashi K, Matsumoto T. Emergence of cephem- and aztreonam-high-resistant Neisseria gonorrhoeae that does not produce beta-lactamase. J Infect Chemother. 2001;7:49-50 pubmed
    ..To date, in gonococcal urethritis, after treatment with third generation cephems and aztreonam, clinical failures caused by resistant N. gonorrhoeae strains have not been reported...
  8. Chen Y, Peng C, Lu P, Tsai J, Chen T. In vitro activities of antibiotic combinations against clincal isolates of Pseudomonas aeruginosa. Kaohsiung J Med Sci. 2004;20:261-7 pubmed
    ..The purpose of the present study was to determine the in vitro activities of piperacillin, cefepime, aztreonam, amikacin, and ciprofloxacin alone and in combination against 100 clinical isolates of P...
  9. Wilcox M, Corey G, Talbot G, Thye D, Friedland D, Baculik T. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65 Suppl 4:iv53-iv65 pubmed publisher
    ..CI), -10%] in the clinical cure rate of ceftaroline fosamil monotherapy to that achieved with vancomycin plus aztreonam combination therapy in the clinically evaluable (CE) and modified intent-to-treat (MITT) analysis populations...
  10. Corey G, Wilcox M, Talbot G, Thye D, Friedland D, Baculik T. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65 Suppl 4:iv41-51 pubmed publisher
    ..cure rate achieved with ceftaroline fosamil monotherapy compared with that achieved with vancomycin plus aztreonam in the clinically evaluable (CE) and modified intent-to-treat (MITT) patient populations...
  11. Livermore D, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2011;55:390-4 pubmed publisher
    Combinations of NXL104 with ceftazidime and aztreonam were tested against carbapenem-resistant members of the Enterobacteriaceae...
  12. Ellis Grosse E, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005;41 Suppl 5:S341-53 pubmed
    ..skin-structure infections (cSSSI) determined the safety and efficacy of tigecycline versus that of vancomycin-aztreonam. Patients received tigecycline (100 mg, followed by 50 mg intravenously twice daily) or vancomycin (1 g ..
  13. Hunfeld K, Weigand J, Wichelhaus T, Kekoukh E, Kraiczy P, Brade V. In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia burgdorferi. Int J Antimicrob Agents. 2001;17:203-8 pubmed
    ..Our study explored the in vitro susceptibility of B. burgdorferi to mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid...
  14. Elborn J, Henig N. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine. Expert Opin Pharmacother. 2010;11:1373-85 pubmed publisher
    ..This review describes the development (2003 - 2010) of aztreonam lysine 75 mg powder and solvent for nebulizer solution (AZLI; Cayston), an aerosolized formulation of the ..
  15. Breedt J, Teras J, Gardovskis J, Maritz F, Vaasna T, Ross D, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother. 2005;49:4658-66 pubmed
    ..50 mg intravenously twice daily) or the combination of vancomycin 2 g/day (1 g intravenously twice daily) and aztreonam 4 g/day (2 g intravenously twice daily) for up to 14 days...
  16. Baltch A, Bassey C, Hammer M, Smith R, Conroy J, Michelsen P. Synergy with cefsulodin or piperacillin and three aminoglycosides or aztreonam against aminoglycoside resistant strains of Pseudomonas aeruginosa. J Antimicrob Chemother. 1991;27:801-8 pubmed
    ..were tested for synergy with cefsulodin or piperacillin plus amikacin, tobramycin, gentamicin or aztreonam by the agar dilution technique...
  17. Yu Q, Griffin E, Moreau Marquis S, Schwartzman J, Stanton B, O Toole G. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells. J Antimicrob Chemother. 2012;67:2673-81 pubmed publisher
    b>Aztreonam for inhalation solution (AZLI) was recently approved by the FDA for treating cystic fibrosis (CF) patients infected with Pseudomonas aeruginosa...
  18. Sass A, Everaert A, Van Acker H, Van den Driessche F, Coenye T. Targeting the Nonmevalonate Pathway in Burkholderia cenocepacia Increases Susceptibility to Certain β-Lactam Antibiotics. Antimicrob Agents Chemother. 2018;62: pubmed publisher
    ..i>B. cenocepacia K56-2dxr showed markedly increased susceptibility to the β-lactam antibiotics aztreonam, ceftazidime, and cefotaxime, while susceptibility to other antibiotics was not (or was much less) affected; ..
  19. Kyriacou S, Brownlow W, Xu X. Using nanoparticle optics assay for direct observation of the function of antimicrobial agents in single live bacterial cells. Biochemistry. 2004;43:140-7 pubmed
    ..We have demonstrated that the number of Ag nanoparticles accumulated in cells increases as the aztreonam (AZT) concentration increases and as incubation time increases, showing that AZT induces the sized ..
  20. Reck F, Bermingham A, Blais J, Capka V, Cariaga T, Casarez A, et al. Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. Bioorg Med Chem Lett. 2018;28:748-755 pubmed publisher
    ..However, existing first generation monobactam drugs like aztreonam have limited clinical utility against MBL-expressing strains because they are impacted by serine β-lactamases (..
  21. Gibson R, Retsch Bogart G, Oermann C, Milla C, Pilewski J, Daines C, et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2006;41:656-65 pubmed
    b>Aztreonam lysinate for inhalation (AI) is a novel monobactam formulation being investigated for pulmonary Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF)...
  22. Nichols D, Happoldt C, Bratcher P, Caceres S, Chmiel J, Malcolm K, et al. Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis. J Cyst Fibros. 2017;16:358-366 pubmed publisher
    ..Ongoing administration of azithromycin associates with reduced ability of inhaled tobramycin, as compared with aztreonam, to improve lung function and quality of life in a completed clinical trial...
  23. Jacqueline C, Howland K, Chesnel L. In vitro activity of ceftolozane/tazobactam in combination with other classes of antibacterial agents. J Glob Antimicrob Resist. 2017;10:326-329 pubmed publisher
    ..aeruginosa isolates. Combinations of ceftolozane/tazobactam with aztreonam, amikacin, tigecycline and meropenem resulted in synergistic effects in some of the bacterial strains tested...
  24. Ozgumus O, Caylan R, Tosun I, Sandalli C, Aydin K, Koksal I. Molecular epidemiology of clinical Pseudomonas aeruginosa isolates carrying IMP-1 metallo-beta-lactamase gene in a University Hospital in Turkey. Microb Drug Resist. 2007;13:191-8 pubmed
    ..Piperacillin/tazobactam was the only effective drug in antimicrobial susceptibility testing. No aztreonam-resistant IMP and VIM producers were detected to produce an extended-spectrum beta-lactamase (ESBL)...
  25. Mangat C, Boyd D, Janecko N, Martz S, Desruisseau A, Carpenter M, et al. Characterization of VCC-1, a Novel Ambler Class A Carbapenemase from Vibrio cholerae Isolated from Imported Retail Shrimp Sold in Canada. Antimicrob Agents Chemother. 2016;60:1819-25 pubmed publisher
    ..Purified VCC-1 was found to hydrolyze penicillins, 1st-generation cephalosporins, aztreonam, and carbapenems, whereas 2nd- and 3rd-generation cephalosporins were poor substrates...
  26. Gilbert E, Zembower T, Rhodes N, Qi C, Reiner S, Malczynski M, et al. Factors contributing to vancomycin-resistant Enterococcus spp. horizontal transmission events: exploration of the role of antibacterial consumption. Diagn Microbiol Infect Dis. 2017;89:72-77 pubmed publisher
    ..Stepwise-multivariate linear regression revealed that aztreonam consumption was associated with a lower rate of transmissions in the medical intensive care unit (P=0...
  27. Sy S, Derendorf H. Experimental design and modelling approach to evaluate efficacy of β-lactam/β-lactamase inhibitor combinations. Clin Microbiol Infect. 2018;24:707-715 pubmed publisher
    ..To discuss the experimental design and modelling strategies for two-drug combinations, using ceftazidime- and aztreonam-avibactam combinations, as examples...
  28. Diaz N, Suarez D, Sordo T. Molecular dynamics simulations of class C beta-lactamase from Citrobacter freundii: insights into the base catalyst for acylation. Biochemistry. 2006;45:439-51 pubmed
    ..dynamics (MD) simulations of the class C beta-lactamase from Citrobacter freundii and its Michaelis complex with aztreonam. Four different configurations of the active site were modeled in aqueous solution, and their relative stability ..
  29. Murase T. [Aztreonam or gentamicin combined with piperacillin as empiric antibiotic therapy during neutropenia of patients with hematologic diseases]. Kansenshogaku Zasshi. 1992;66:121-6 pubmed
    ..with two randomly assigned antibiotic combinations of either piperacillin plus gentamicin or piperacillin plus aztreonam. Eleven of the 22 febrile episodes treated with piperacillin plus gentamicin and 12 of the 20 febrile episodes ..
  30. Pathak V, Hurtado Rendon I, Smina M. Necrotizing pneumonia caused by group C streptococci in a young adult. Respir Care. 2012;57:454-6 pubmed publisher
    ..Thus, we are reporting a rare case of necrotizing group C beta hemolytic streptococcal pneumonia in a young healthy adult with no risk factors. ..
  31. Zhu M, Yang G, Li A, Zong L, Dong Z, Lu J, et al. Identification and molecular characterization of Escherichia coli blaSHV genes in a Chinese teaching hospital. Gene. 2017;600:29-35 pubmed publisher
    ..activity to the broad-spectrum penicillin (ampicillin or piperacillin), ceftazidime, ceftriaxone, cefotaxime and aztreonam. blaSHV-195 and blaSHV-11 had similar resistant characteristics with high hydrolysis ..
  32. Livermore D, Mushtaq S, Warner M, Woodford N. Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases. J Antimicrob Chemother. 2015;70:3032-41 pubmed publisher
    ..UK clinical isolates; MICs were determined by CLSI agar dilution for OP0595 alone or combined at 1-4 mg/L with aztreonam, biapenem, cefepime or piperacillin...
  33. van Delden C, Page M, Köhler T. Involvement of Fe uptake systems and AmpC ?-lactamase in susceptibility to the siderophore monosulfactam BAL30072 in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013;57:2095-102 pubmed publisher
    ..These mutants were cross-resistant to aztreonam and ceftazidime. Similar mutants were obtained after selection at >16× the MIC in iron-sufficient conditions...
  34. de Oliveira F, Pires B, de Cássia Ferreira de Almeida Silva K, de Carvalho B, Teixeira L, de Paula G, et al. Prevalence, Antimicrobial Susceptibility, and Clonal Diversity of Pseudomonas aeruginosa in Chronic Wounds. J Wound Ostomy Continence Nurs. 2017;44:528-535 pubmed publisher
    ..aeruginosa isolates were detected in chronic wounds, and 3 were multidrug resistant (6%). Resistance to aztreonam and ciprofloxacin was observed in 48% and 27% of isolates, respectively...
  35. Wagner B, Heaton A, Flink J. Cefotetan disodium-induced hemolytic anemia. Ann Pharmacother. 1992;26:199-200 pubmed
    ..Cefotetan should be added to the list of drugs known to cause hemolytic anemia. Monitoring for hemolysis should be considered for patients who receive multiple courses of therapy. ..
  36. Hakenbeck R, Tornette S, Adkinson N. Interaction of non-lytic beta-lactams with penicillin-binding proteins in Streptococcus pneumoniae. J Gen Microbiol. 1987;133:755-60 pubmed
    The monobactam aztreonam and the cephalosporin ceftazidime, beta-lactam antibiotics that possess the same side chain R1, showed unusual effects on exponentially growing pneumococci compared to other beta-lactams...
  37. Raponi G, Nazzari G, Lun M, Lorino G, Valentini T, Bronzini M, et al. Immunization of mice with antibiotic treated Escherichia coli. J Chemother. 1991;3 Suppl 1:136-40 pubmed
    ..coli ATCC 25922 either exposed or not to 0.1 x MIC of aztreonam. A group of mice injected with sterile saline only served as control...
  38. Hanberger H, Nilsson L, Maller R, Nilsson M. Pharmacodynamics of beta-lactam antibiotics on gram-negative bacteria: initial killing, morphology and postantibiotic effect. Scand J Infect Dis Suppl. 1990;74:118-23 pubmed
    ..The PAE of aztreonam, cefotaxime, ceftazidime, imipenem, mecillinam and piperacillin on Enterobacter cloacae, Escherichia coli, ..
  39. Giuliano C, Kale Pradhan P, Johnson L. Early response of ceftaroline fosamic in the treatment of soft-tissue infections. Expert Rev Clin Pharmacol. 2012;5:509-12 pubmed publisher
    ..Future trials utilizing this new end point in prospective ABSSSI trials will show over time the true value of such an end point. ..
  40. Plosker G. Aztreonam lysine for inhalation solution: in cystic fibrosis. Drugs. 2010;70:1843-55 pubmed publisher
    b>Aztreonam is a monobactam antibacterial with bactericidal activity against a wide range of aerobic Gram-negative bacteria, including Pseudomonas aeruginosa...
  41. Wright H, Bonomo R, Paterson D. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?. Clin Microbiol Infect. 2017;23:704-712 pubmed publisher
    ..ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/cilastatin/relebactam, meropenem/vaborbactam and aztreonam/avibactam; cefiderocol, a siderophore cephalosporin; plazomicin and eravacycline...
  42. McKinnon P, Sorensen S, Liu L, Itani K. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother. 2006;40:1017-23 pubmed
    ..Linezolid therapy was associated with improved clinical outcomes and significantly lower treatment costs than was vancomycin. The largest cost advantage was demonstrated in patients with documented MRSA cSSTIs. ..
  43. Romano A, Gaeta F, Valluzzi R, Maggioletti M, Caruso C, Quaratino D. Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell-mediated hypersensitivity to penicillins. J Allergy Clin Immunol. 2016;138:179-86 pubmed publisher
    ..8% to 31.2% and an absence of cross-reactivity with aztreonam. We sought to evaluate the possibility of using cephalosporins and aztreonam in subjects with documented delayed ..
  44. Amali M, Jenkins R, Meng X, Faulkner L, Whitaker P, Peckham D, et al. Assessment of Antipiperacillin IgG Binding to Structurally Related Drug Protein Adducts. Chem Res Toxicol. 2017;: pubmed publisher
    ..Mass spectrometry was used to show the drugs (amoxicillin, flucloxacillin, benzyl penicillin, aztreonam, and piperacillin) bind to similar lysine residues on the protein carrier bovine serum albumin...
  45. Wainwright C, Quittner A, Geller D, Nakamura C, Wooldridge J, Gibson R, et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. J Cyst Fibros. 2011;10:234-42 pubmed publisher
    Previous aztreonam for inhalation solution (AZLI) studies included patients with cystic fibrosis, Pseudomonas aeruginosa (PA) airway infection, and forced expiratory volume in 1s (FEV(1)) 25% to 75% predicted...
  46. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 2001;32:402-12 pubmed
    ..A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7-21 days...
  47. Mirelis B, Rivera A, Miro E, Mesa R, Navarro F, Coll P. A simple phenotypic method for differentiation between acquired and chromosomal AmpC beta-lactamases in Escherichia coli. Enferm Infecc Microbiol Clin. 2006;24:370-2 pubmed
    ..of scattered colonies located near the edge of the inhibition halo of cefoxitin, cefotaxime, ceftazidime and aztreonam, and a double-disc synergy test using cloxacillin (500 mg) to inhibit AmpC enzymes...
  48. Wang L, Nakamura H, Kage Nakadai E, Hara Kudo Y, Nishikawa Y. Prevalence, antimicrobial resistance and multiple-locus variable-number tandem-repeat analysis profiles of diarrheagenic Escherichia coli isolated from different retail foods. Int J Food Microbiol. 2017;249:44-52 pubmed publisher
    ..All isolates were susceptible to aztreonam. Of the resistant strains, 44% (22/50) demonstrated resistance to >3 antimicrobial agents...
  49. Meyers B, Wilkinson P, Mendelson M, Bournazos C, Tejero C, Hirschman S. Pharmacokinetics of aztreonam in healthy elderly and young adult volunteers. J Clin Pharmacol. 1993;33:470-4 pubmed
    b>Aztreonam is a monobactam exhibiting an antibacterial spectrum similar to that of the aminoglycosides, with activity against aerobic gram-negative bacilli, and is the only related drug that may be given to patients hypersensitive to beta-..
  50. Cardoso T, Almeida M, Carratalà J, Aragão I, Costa Pereira A, Sarmento A, et al. Microbiology of healthcare-associated infections and the definition accuracy to predict infection by potentially drug resistant pathogens: a systematic review. BMC Infect Dis. 2015;15:565 pubmed publisher
    ..would be adequate in only 73-76 % of the cases; an alternative regimen with piperacillin-tazobactam or aztreonam plus azithromycin would increase antibiotic adequacy rate to 90 %...
  51. Ourghanlian C, Soroka D, Arthur M. Inhibition by Avibactam and Clavulanate of the β-Lactamases KPC-2 and CTX-M-15 Harboring the Substitution N132G in the Conserved SDN Motif. Antimicrob Agents Chemother. 2017;61: pubmed publisher
    ..CTX-M-15 was moderately affected by the substitution N132G, but that of ceftazidime, ceftaroline, and aztreonam was drastically reduced...
  52. Blahova J, Kralikova K, Krcmery V, Jezek P. Low-Frequency transduction of imipenem resistance and high-frequency transduction of ceftazidime and aztreonam resistance by the bacteriophage AP-151 isolated from a Pseudomonas aeruginosa strain. J Chemother. 2000;12:482-6 pubmed
    ..aeruginosa. Resistance to cefotaxime, ceftazidime, aztreonam, imipenem and meropenem was transduced as a block, at different frequencies, to two P. aeruginosa strains...
  53. Estep P, Ferreira J, Dupree L, Aldridge P, Jankowski C. Impact of an antimicrobial stewardship initiative to evaluate β-lactam allergy in patients ordered aztreonam. Am J Health Syst Pharm. 2016;73:S8-13 pubmed publisher
    ..initiative (ASQI) focusing on allergy assessment in patients with a documented β-lactam allergy prescribed aztreonam was conducted...